Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
0 hedge funds and large institutions have $0 invested in Rosetta Genomics Ltd. in 2021 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $1K → $0 (-$1K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$1K |
ROSG Hedge Fund Activity: Q3 2021 in Review
0 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q3 2021, worth a combined $0 — down 100% from $1K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ROSG and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Highlander Capital Management, exiting entirely with an estimated $1K sold.
- 0 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q3 2021, down from 1 in Q2 2021.
- Funds reported $0 of Rosetta Genomics Ltd. stock for Q3 2021, down 100% quarter-over-quarter.
- 0 funds opened new Rosetta Genomics Ltd. positions in Q3 2021 and 1 closed out, a net change of -1 holder.
- The largest Rosetta Genomics Ltd. seller in Q3 2021 was Highlander Capital Management, an estimated $1K sold.
Based on aggregated 13F filings for Q3 2021.